The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2025 | Final analysis of the CAPTIVATE study and comparisons with the SEQUOIA trial
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, from Alfred Hospital and Monash University, Melbourne, Australia, discusses the final analysis of the Phase II CAPTIVATE study (NCT02910583), which investigated the combination of ibrutinib and venetoclax as a limited-duration therapy for chronic lymphocytic leukemia (CLL). He compares findings to those in the SEQUOIA trial (NCT03336333), which found a progression-free survival rate of 72% for patients with del(17p) treated with continuous zanubrutinib. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the CAPTIVATE study is one of those studies that I spoke about where there is limited duration therapy. It’s a combination of ibrutinib and venetoclax as frontline treatment and it enrolls patients with or without 17p disease. So that’s a study that has even longer follow up than what we have now. And what that showed is that you would take the combination of ibrutinib and venetoclax and you have a 17p deletion...
So the CAPTIVATE study is one of those studies that I spoke about where there is limited duration therapy. It’s a combination of ibrutinib and venetoclax as frontline treatment and it enrolls patients with or without 17p disease. So that’s a study that has even longer follow up than what we have now. And what that showed is that you would take the combination of ibrutinib and venetoclax and you have a 17p deletion. You have a median progression-free survival of five years, which is good, but not as good as continuous zanubrutinib in this study, which is 72%. There is one difference though. You will do relapse on continuous BTK therapy, and then at a time of relapse, you’re resistant to BTK inhibitors. In CAPTIVATE, patients take 12 months of treatment, and then they stop the therapy, and when they relapse, they remain sensitive to retreatment. So I think they’re both really good strategies for patients with 17p deletion CLL. One of them gives you a slightly longer progression-free survival, but you’re resistant to BTK inhibitors at the end of treatment. The other one gives you a slightly shorter progression-free survival, but it’s limited duration and you can be retreated at the time of relapse.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
